Navigation Links
Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Date:10/13/2010

NEW YORK, Oct. 13 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today the completion of its previously announced underwritten public offering of 5,500,000 shares of Common Stock, as well as 825,000 additional shares of its Common Stock pursuant to the full exercise of the over-allotment option granted to the underwriter.  The total proceeds of the offering (before estimated offering expenses) were approximately $175.1 million.  Citi acted as the sole book-running manager for the offering.  The shares were offered by Regeneron under the Company's shelf registration statement.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.  Copies of the prospectus supplement and accompanying prospectus related to this offering may be obtained by sending a request to the offices of Citi at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, telephone number (800) 831-9146.  Alternatively, these documents are available by visiting EDGAR on the SEC website at www.sec.gov.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Forward-Looking Statements: Regeneron Pharmaceuticals, Inc.This news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties. These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Astellas, the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended June 30, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.RegeneronMichael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Increases Size of Public Offering of Common Stock
2. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
3. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
4. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
5. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
6. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Regeneron Reports Third Quarter 2009 Financial and Operating Results
10. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
11. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths ... Assembly Bill (AB) 1512, which proposes a tax on prescription opioids to fund ...
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
Breaking Medicine News(10 mins):